Where does Omeros Corporation rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Omeros Corporation ranks #4,905 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Omeros Corporation hold?

Omeros Corporation holds 71 US utility patents granted between 2015 and 2025, spanning 21 technology areas.

What is Omeros Corporation's Innovation Score?

Omeros Corporation has an Innovation Score of 50.6 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Omeros Corporation's patent grant rate increasing or decreasing?

Omeros Corporation's recent grant velocity is -14% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Omeros Corporation's patents?

Omeros Corporation's patents average 16.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Omeros Corporation patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Omeros Corporation

Q: What technology areas does Omeros Corporation focus on?

Omeros Corporation's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 60 patents. Grants appear in 21 CPC subclasses total.

USPTO PatentsView assignee record - 71 granted patents across 21 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Omeros ranks #4,905 of 49,997 tracked US assignees by granted-patent volume, with 71 patents across 21 technology areas.

#4,905
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.6/100): 16.0
avg claims per patent: -14%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R4905 · US Corporation #4,905 · 71 grants

GRANTS-SMALL · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 71 grants
TOP-DECILE #4,905/49,997
PHOTO-FINISH National University…
CPC-FOCUS A61P · 21 areas
INNOV-PAR 50.6/100
CLAIMS-RICH 16.0 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -14% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: National University OF Defense Technology (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
ION Geophysical · near

51
Everdisplay… · near

51
Mirka · near

51
Omeros · this assignee

51
Shanghai Biren… · near

51
3D Lighting… · lowest

7

What this shows Omeros's Innovation Score is 50.6/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Omeros's grants concentrate

Omeros Corporation is a focused PatentsView assignee: 21 CPC subclasses with 84.5% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2024 (11 grants) versus a trough of 3 in 2019. By volume, Omeros sits between National University OF Defense Technology and Pukyong National University Industry-University Cooperation Foundation.

Omeros's three-year grant acceleration

Omeros Corporation shows 21 grants in 2022–2024 against only 14 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

National Universi…

71
NGM Biopharmaceut…

71
Nuvera Fuel Cells

71
Ohio State Univer…

71
PME IP PTY

71
Pro-iroda Industr…

71
Proxense

71
Pukyong National…

71
Omeros ◀

71

What this shows Omeros holds 71 patents at rank #4,905, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Omeros

By rank, the assignees closest to #4,905 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Omeros's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Omeros, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (51 here).

Everdisplay Optronics (Shanghai) Co., Ltd 51 Mirka Ltd 51 Shanghai Biren Technology Co., Ltd 51 ION Geophysical Corporation 51

Similar claim depth

Nearest assignees by average claims per patent (16.0 here).

Berlin Heart GmbH 16.0 avg Leedarson Lighting Co., Ltd. 16.0 avg Suzhou Opple Lighting Co., Ltd. 16.0 avg OVH 16.0 avg

Omeros's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Omeros Corporation patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	9	12.7%
2016	9	12.7%
2017	9	12.7%
2018	7	9.9%
2019	3	4.2%
2020	6	8.5%
2021	5	7.0%
2022	5	7.0%
2023	5	7.0%
2024	11	15.5%
2025partial year	2	2.8%

Which technologies does Omeros Corporation patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 60

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 56

C07K - Peptides 39

C07D - Heterocyclic Compounds 16

C12Y - Enzymes 13

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 12

Y02A - Technologies FOR Adaptation TO Climate Change 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C01P - Indexing Scheme Relating TO Structural AND Physical Aspects OF Solid Inorganic Compounds 4

H01F - MAGNETS; INDUCTANCES; TRANSFORMERS; Selection OF Materials FOR Their Magnetic Properties 4

C09K - Materials FOR Miscellaneous Applications, NOT Provided FOR Elsewhere 4

C01F - Compounds OF THE Metals Beryllium, Magnesium, Aluminium, Calcium, Strontium, Barium, Radium, Thorium, OR OF THE Rare-earth Metals 4

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 4

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

Top 15 of 21 technology areas

Where it ranks

Overall rank by patents

#4,905

of 49,997 tracked assignees

Innovation Score

50.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Omeros Corporation's patent record in context - here's where to go next.

Omeros Corporation's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84.5% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #4,905 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Omeros Corporation against National University OF Defense Technology, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.